GSMA and Sónar Release First Details of xside
23.10.2019 14:00:00 EEST | Business Wire | Press release
The GSMA’s successful Four Years From Now (4YFN) start-up platform and Sónar, the international festival devoted to advanced music, creativity and technology, today announced further details of their hotly anticipated co-curated event, xside. Taking place within the 4YFN venue, from 24-26 February 2020 at Fira Montjuïc, in parallel to 4YFN and MWC Barcelona 2020, xside is a new gathering including conference, networking and music to explore the role technology, design and innovation play in the future of creativity, cultures and business.
As the creative heart of 4YFN and MWC Barcelona, xside is designed to create links between Sónar’s audience of creative communities, and the technological and entrepreneurial attendees of the world’s largest mobile event. It is the first integrated convergence event of its kind on this scale, co-created by leading event brands of music, creativity, technology, design and entrepreneurship. xside will welcome over 25,000 attendees across three days and over 5,000 revellers each night.
“xside is a fantastic meeting of cultures, industries and creative minds, bringing together two of Barcelona's premier events, each representing significant but distinct communities,” said John Hoffman, CEO GSMA Ltd. “By launching such a hub of creative excellence, that celebrates the ideas, skills and people that are leading future change, we will shape the relationship between design, culture and technology for the benefit of everyone these industries as well as other sectors.”
“xside is the creative and content hub of the biggest tech week in the world, a ground-breaking gathering to explore the role of technology, design and innovation play in the future of creativity, cultures and business. The collaboration with the GSMA’s 4YFN and MWC Barcelona for the creation and organization of xside, is increasing our long-time effort to increase public awareness of the important role that creativity technology plays in society: changing our present and imagining new futures,” said Ventura Barba, Executive Director Advanced Music, SL (Sónar and Sónar+D).
Design and Creativity Converges with Technology
Celebrating its 20th anniversary next year, the prestigious design and creativity festival OFFF has signed as xside’s first content partner. OFFF will deliver conferences and performances by Berlin-based electronic music composer Ben Lukas Boysen together with digital and new media artists Joëlle Snaith and Joshua Davis.
OFFF is exploring the boundaries of creativity and technology by hosting its prominent conference on stage at xside. The first speakers announced by OFFF are:
- David Vogel, Executive Director, Experience Design, AKQA
- Irene Pereyra and Anton Repponen, Founders, Anton & Irene
- Josue Ibañez, Co-Founder and Interaction Design Director, Cocolab
- Verònica Fuerte, Founder, Hey Studio
By day, the xside experience, co-curated by Sónar, will feature industry discussions and keynotes. Events will include live music, a showcase of immersive technology, interactive art installations and gastronomic delights. When 4YFN and MWC Barcelona close their doors for the day, ‘xside-by-Night’ takes over, with late-night keynotes and a dedicated music stage until 23:00 each night. To accommodate these new changes to the 4YFN programme, the event will double its footprint, moving venue from Hall 8 at Fira Montjuic to the Halls and the courtyard where Sónar by Day is traditionally held.
4YFN is the start-up event of GSMA MWC supporting start-ups, investors and companies to connect and launch new ventures together. Hosted at the same time as MWC Barcelona, the event in Barcelona attracts more than 23,000 attendees, 1000 investors, 700 start-ups and exhibitors and hosts more than 400 speakers.
For more information on how to participate at 4YFN, please visit https://www.4yfn.com/barcelona/xside/. Tickets are on sale now with a 20 per cent off early bird discount at 4YFN.com.
-ENDS-
Notes to Editors
Sónar is a pioneering cultural event focused on electronic music and digital arts. A pioneering festival in terms of content, production and strategy, Sónar has become an international reference point, thanks to its love for combining the avant-garde and experimental, with the newest trends in urban culture. Sónar+D, its congress of creativity, technology and business, was launched in 2013 and runs concurrently to the Barcelona festival as well as other events throughout the year. It attracts more than 20,000 professionals from the creative industries as well as from the world of science and technological innovation.
OFFF was founded in 2000. Today, OFFF has become the most influential creativity festival to attend. OFFF is a community inviting all those who are eager to learn, to participate and get inspired in a three-day journey of conferences, workshops, activities and performances. OFFF hosts innovative and international talents to share their insightful experiences.
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators and nearly 400 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.
For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191023005356/en/
Contact information
Pau Guerrero
+34932360923
PGuerrero@webershandwick.com
Jen Roberts
+34678403933
jroberts@gsma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
